David H. Sherman is the Hans W. Vahlteich Professor of Medicinal Chemistry at the University of Michigan, holding joint appointments in the College of Pharmacy (Department of Medicinal Chemistry), Medical School (Microbiology & Immunology), and College of Literature, Science, and the Arts (Chemistry). He leads the Sherman Lab at the Life Sciences Institute and co-founded the Natural Products Discovery Core. His research focuses on natural product discovery, biosynthetic pathways, and drug development for infectious diseases, cancer, and neurological disorders. Education: PhD in Synthetic Organic Chemistry from Columbia University (1981), BA in Chemistry from UC Santa Cruz (1978). Postdoctoral research at MIT (1984). Research interests include microbial secondary metabolites, enzymatic catalysis (e.g., C-H functionalization, polyketide assembly), and high-throughput drug screening. He pioneered a microbial natural product library with over 50,000 samples. Current projects emphasize developing macrolide antibiotics and advancing compounds toward clinical trials through the Natural Products Biosciences Initiative. Collaborations span global institutions, with a focus on biodiversity conservation and capacity-building in low-income nations. He has mentored 67 PhD students, 60 postdocs, and 85+ undergraduates, fostering interdisciplinary training in chemical biology and microbial biochemistry. Labs/Teams: Sherman Lab (Life Sciences Institute), Center Member at Samuel and Jean Frankel Cardiovascular Center, Center for Computational Medicine and Bioinformatics, Rogel Cancer Center.
Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.
Jeremy K Fox is Associate Professor of Psychology at Montclair State University's College of Humanities and Social Sciences, where he directs the RECAP (Research on Emotion, Coping and Anxiety in Pediatrics) laboratory. His research examines developmental pathways to childhood anxiety and depression. Education includes: PhD in Clinical Psychology, State University of New York at Albany MA in Psychology, State University of New York at Albany BA in Psychology, Johns Hopkins University Research focuses on temperament-environment interactions, emotion regulation deficits, and school-based interventions. Current work investigates parental influences on anxiety development and peer-supported treatment models for minority youth. Articles demonstrate consistent focus on improving mental health service accessibility. Leads graduate training in clinical psychology and mentors doctoral students in anxiety research. RECAP lab investigates affective mechanisms underlying adolescent distress and develops digital interventions for school settings.
Dr. Tobias Hauser is a Professor of Computational Psychiatry at the University of Tübingen, Germany, and a Group Leader at the Max Planck UCL Centre for Computational Psychiatry and Ageing Research. His research spans clinical neuroscience, developmental psychiatry, and computational modeling, focusing on the neurocognitive mechanisms underlying psychiatric disorders like OCD and ADHD. MSc in Psychology (2010), University of Zurich PhD in Psychology (2014), University of Zurich Hauser's work employs a translational approach, integrating clinical, pharmacological, and basic neuroscience to characterize neural network deficiencies in mental health. His developmental perspective investigates how psychiatric symptoms emerge through deviations from canonical brain development trajectories. Recent publications highlight his focus on dopaminergic midbrain activity, frontostriatal myelination, and computational mechanisms of decision-making. These studies utilize techniques like fMRI, EEG, and computational modeling to explore compulsivity, impulsivity, and developmental neurocognitive processes. Sir Henry Dale Fellowship (Wellcome Trust & Royal Society) Research Fellowship (Jacobs Foundation) Kramer-Pollnow Award for ADHD research Hauser leads the Developmental Computational Psychiatry Group and co-founded the Brain Explorer app, a citizen science project investigating brain development and mental health. He actively seeks PostDocs and PhD students for collaborative research in computational psychiatry and cognitive neuroscience.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
J. Anthony Movshon is a Professor at New York University (NYU) in the Department of Psychology and a key member of NYU's Center for Neural Science (CNS). His research focuses on the primate visual system, particularly the encoding and decoding of visual information in cortical areas like V1 and MT, and its role in behavior and perception. Education: Doctorate in Visual Neurophysiology and Psychophysics from Cambridge University Research Interests: Movshon investigates the functional architecture of the visual cortex, emphasizing motion, form, and color processing. His work explores how neural activity relates to perceptual decisions and motor behavior, using electrophysiological recordings, neuroimaging, and computational models. He also studies developmental disorders like amblyopia and their impact on visual system organization. Publications: His recent work spans visual texture selectivity in V2, contextual modulation in neural responses, motion processing in MT, and decoding mechanisms in visual cortex. These studies employ interdisciplinary approaches blending neurophysiology, computational neuroscience, and cognitive modeling. Labs & Collaborations: Movshon leads the Visual Neuroscience Laboratory at NYU, collaborating with researchers such as Michael Hawken, Lynne Kiorpes, and Eero Simoncelli.
Dr. Jeewanie Jayasinghe Arachchige is a Lecturer in the Department of Computer Science at Vrije Universiteit Amsterdam, Faculty of Science. She teaches undergraduate courses including Bachelor Project Computer Science, Professional Development, and Software Engineering Processes for the academic year 2024–2025. Her research focuses on process mining , healthcare informatics , and data security . She applies process mining to analyze healthcare pathways and subpopulation treatment variations, develops explainable AI frameworks for predictive analytics, and examines data governance in emerging architectures like Data Lakehouses. Her work intersects legal informatics, particularly formalizing Sri Lankan civil court processes using ontology engineering. Recent publications highlight trends in balancing simplicity and complexity in process modeling, Industry 4.0 healthcare applications, and cybersecurity in model-driven web development. She has contributed to over 20 peer-reviewed articles since 2006, spanning topics from service-oriented architectures to value network analysis. Her teaching and research emphasize practical applications of IT in healthcare, legal systems, and enterprise environments. No ancillary activities are currently recorded.
Thomas Perlmann is a Professor in Molecular Developmental Biology at the Karolinska Institutet , leading research at the Department of Cell and Molecular Biology and serving as Director of the Stockholm Branch of the Ludwig Institute for Cancer Research. He also holds the position of Secretary General of the Nobel Assembly and Nobel Committee for Physiology or Medicine since 2016. Ph.D. , Karolinska Institutet, 1991 M.Sc. , Stockholm University, 1987 Research Interests : The Perlmann lab investigates the specification and maintenance of dopamine neurons in the central nervous system, with a focus on transcriptional regulation , signaling pathways , and regenerative medicine applications for Parkinson’s disease and other neurodegenerative disorders. His work bridges developmental biology and neuroscience , emphasizing the role of transcription factors in neuronal identity and function. Recent Research Trends : Perlmann’s recent publications highlight the use of single-cell RNA sequencing to dissect dopamine neuron heterogeneity , epigenetic regulation during development, and transcriptomic changes in Parkinson’s disease models. His studies increasingly leverage multiomics and bioinformatics to map neuronal lineage trajectories and gene expression dynamics. Scientific Awards : Royal Medal by HM the King (2025) Nicholson Lecturer, Rockefeller University (2011) Göran Gustafsson Prize in Molecular Biology (1999) Eric K. Fernström Young Investigator Prize (1997) Advising & Collaborations : While no student names are explicitly listed, Perlmann collaborates extensively with researchers such as Malin Parmar , Agnete Kirkeby , and Per Svenningsson on projects related to neuronal development and cell therapy . His lab receives funding from institutions like the Ludwig Institute for Cancer Research . Labs & Teams : The Perlmann Lab at Karolinska Institutet includes researchers like Linda Gillberg , Laura Lahti , and Behzad Yaghmaeian Salmani , who work on mouse models , single-cell transcriptomics , and bioinformatics to study dopamine neuron biology.
Hyun (Michel) Koo is a Professor at the University of Pennsylvania School of Dental Medicine , with affiliations in the Department of Orthodontics , Division of Community Oral Health , and Division of Pediatric Dentistry . As Co-Founder and Co-Director of the Center for Innovation & Precision Dentistry (CiPD) , he leads interdisciplinary efforts merging bioengineering, nanotechnology, and oral health research. Education : DDS and PhD Research Focus : Biofilms, bacterial-fungal interactions, and nanotechnology for oral disease prevention Leadership : Co-Director of CiPD; key roles in training programs like NIDCR-sponsored R90 and T90/R90 Dr. Koo’s research explores biofilm mechanisms in oral infectious diseases, particularly childhood caries, through engineering methods and microrobotics . His team developed micron-scale robots for automated biofilm eradication and FDA-approved nanoparticles for caries prevention. Collaborations with Penn Engineering, including Dr. Daeyeon Lee and Dr. Kacy Cullen, emphasize translational approaches. The 15 most recent publications highlight his work in nanorobotics , interkingdom biofilms , and precision diagnostics . Articles span 2025–2024 and address topics like adaptive micromotors , biofilm matrix degradation , and single-cell microbial interactions . These emphasize his focus on targeted therapies and biofilm microenvironment engineering . Key Awards : Elected Fellow, American Association for the Advancement of Science (AAAS) IADR Distinguished Scientist Award for innovative dental research Dr. Koo trains next-generation researchers through the CiPD NIDCR T90/R90 Postdoctoral Training Program , mentoring fellows like Smruti Nair (ACE2 Chewing Gum development) and Zhi Ren (K99 awardee). His work intersects with Penn Health-Tech, CT3N , and Penn Institute for Biomedical Informatics , fostering transdisciplinary innovation.
Brooke Hudspeth, PharmD, is an Associate Professor and Chief Practice Officer at the University of Kentucky (UK) College of Pharmacy. She oversees community pharmacy initiatives and serves as acting President of the Kentucky Pharmacists Association (KPhA). Her roles include mentoring pharmacy students and residents as a preceptor, and leading collaborative projects with organizations like the American Pharmacists Association Foundation, Kroger Co., and the CDC. Educationally, she holds a Doctor of Pharmacy from the UK College of Pharmacy, alongside PGY1/PGY2 Community-based Pharmacy Practice Residencies from the same institution. Her research focuses on diabetes prevention, obesity, and pharmacist-driven clinical services, particularly through expanding the National Diabetes Prevention Program (NDPP) to five U.S. states via a $7.5M CDC grant. Research interests emphasize health disparities, vaccine accessibility, and optimizing pharmacist roles in self-care conditions. Notable projects include influenza point-of-care testing and pharmacy partnerships during the pandemic. Her work bridges academic innovation with real-world healthcare challenges, advocating for policy changes to enhance pharmacist payment for clinical services. Despite no explicitly listed awards, her impactful grant-funded projects reflect significant contributions to public health. She advises students and residents while leading residency expansion initiatives. Collaborations with major institutions underscore her role in advancing pharmacy practice and education nationally. Hudspeth’s lab/team is embedded within UK’s College of Pharmacy, focusing on translational research to improve patient care through pharmacist-led interventions. Future work includes expanding telehealth pharmacy services and addressing healthcare workforce shortages.
Paul O'Toole is a Professor of Microbial Genomics and Principal Investigator at the APC Microbiome Ireland, University College Cork. His research focuses on the gut microbiome's role in health, aging, and disease, particularly in the context of diet and probiotics. He leads projects like the ELDERMET study on elderly nutrition and the NU-AGE project exploring Mediterranean diets' anti-aging effects. He holds a BA (Mod.) from Trinity College Dublin and a PhD from Lund University, with postdoctoral training in Canada and New Zealand. Key grants include studies on dairy-derived microbiota, probiotic strain improvement, and microbiome analysis in aging populations. He has published extensively on Lactobacillus genomics, gut-brain interactions, and microbiome-driven health outcomes. His work bridges fundamental microbiology with clinical applications, emphasizing translational research. Scientific highlights include discovering microbiome links to cognitive decline, demonstrating dietary modulation of gut microbes to combat obesity, and identifying keystone species in healthy aging. He advocates for sustainability in conservation and food systems, reflecting his interdisciplinary approach to global health challenges.
Calliope Dendrou is an Associate Professor in Clinical Pathology and Inflammation at the Kennedy Institute of Rheumatology (KIR), University of Oxford, leading the Immune Disease Multiomics Laboratory. She previously held a Wellcome & Royal Society Sir Henry Dale Fellowship at the University of Oxford’s Centre for Human Genetics before joining KIR in 2023. Her research focuses on immune disease mechanisms using multiomics approaches, including genomic profiling to identify therapeutic targets across tissues and immune-mediated diseases. She co-leads large-scale projects like the Oxford-J&J Cartography Consortium and the Chan Zuckerberg Initiative’s LEGACY Network, and teaches on the MSc in Genomic Medicine program. Educational Background: BSc (Biology, Imperial College London, 2005; Forbes Memorial Medal Winner); PhD in Infection & Immunity (University of Cambridge, 2010). Postdoctoral training at the Weatherall Institute of Molecular Medicine under Prof. Lars Fugger. Research interests include immunogenetics, cytokine signaling pathways, drug repositioning, and cross-disease pathophysiology. Her work integrates single-cell and spatial transcriptomics to dissect immune-cell interactions in diseases like rheumatoid arthritis, inflammatory bowel disease, and celiac disease. Recent articles highlight her contributions to understanding vaccine adjuvant responses, Th17 cell roles in spondyloarthritis, and immune-epithelial networks in celiac disease. Collaborations emphasize multi-omic data analysis (e.g., Panpipes pipeline) and translational studies toward precision medicine. Awards: Forbes Memorial Medal (BSc), Wellcome & Royal Society Sir Henry Dale Fellowship. Leadership roles include Equality, Diversity, and Inclusion Champion and 'Single-Cell & Spatial Omics for Precision Medicine' Module Lead. Lab & Teams: Immune Disease Multiomics Lab at KIR. Active in collaborative initiatives such as the LEGACY Network, focusing on large-scale immune profiling in ancestrally diverse populations.
Dr. Ahmet Acar is an Associate Professor at the Department of Biological Sciences, Middle East Technical University (METU), Ankara, Turkey. He leads the Cancer Precision Medicine and Drug Resistance Laboratory, focusing on understanding mechanisms of drug resistance in cancer. His research integrates experimental models, next-generation sequencing, and deep learning to address clinical challenges in cancer therapy. Dr. Acar holds a B.Sc. from METU's Biological Sciences department and a Ph.D. from the Cancer Research UK Manchester Institute. He completed postdoctoral training at the Institute of Cancer Research, London, and the University of Manchester. Research Interests: Drug resistance mechanisms, precision oncology, tumor microenvironment modeling, patient-derived organoids, computational pathology, and evolutionary cancer biology. His lab develops 2D/3D co-culture systems, PDO biobanks, and AI-driven histopathology tools to improve treatment strategies. Recent Work Trends: Recent publications emphasize tumor evolution modeling, matrix mechanics in drug resistance, and AI applications in histopathology. Collaborations with hospitals in Turkey and Europe support PDO biobank initiatives. His team explores evolutionary steering strategies to exploit collateral drug sensitivities. Labs/Teams: Precision Medicine and Drug Resistance Lab at METU focuses on interdisciplinary approaches combining wet-lab experiments with computational methods. Current projects include ex vivo tumor modeling and AI-driven diagnostic tools for oncology.
Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
David S. Eisenberg is a Professor of Chemistry and Biochemistry and Biological Chemistry at the University of California, Los Angeles, where he also serves as Director of the UCLA-DOE Institute for Genomics and Proteomics and as an HHMI Investigator. His research focuses on protein interactions, particularly the structural basis for conversion of normal proteins to the amyloid state and conversion of prions to the infectious state. Dr. Eisenberg earned his undergraduate degree in biochemical sciences from Harvard College and his D.Phil. degree in theoretical chemistry from Oxford University on a Rhodes Scholarship. His postdoctoral research was on ice and water with Walter Kauzmann at Princeton and in protein crystallography with Richard Dickerson. He joined the UCLA faculty after his postdoctoral studies. Dr. Eisenberg and his research group focus on protein interactions in amyloid and prion diseases. These diseases involve protein aggregation where normal functional proteins convert to abnormal aggregated forms. Systemic amyloid diseases like dialysis-related amyloidosis result from fiber accumulation until organ failure, while neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and prion conditions appear to be caused by smaller oligomers. In 2005, his team determined the atomic-level structure for the amyloid fiber spine, revealing a 'steric zipper' of two parallel beta sheets packed across a dry interface. Since then, they've determined approximately 90 amyloid spines from 15 disease-related proteins. In 2010, they identified the structure of a toxic amyloid-related oligomer consisting of six anti-parallel beta strands forming a cylindrical barrel. His recent publications demonstrate continued innovation in amyloid research, with focus areas including structural prediction of amyloid formation, mechanisms of tau fibril disassembly in Alzheimer's disease, cryo-EM analysis of amyloid polymorphism, and structure-based design of inhibitors for amyloid toxicity. His work integrates computational, structural, and biochemical approaches to understand protein aggregation across multiple disease contexts. Dr. Eisenberg has received numerous prestigious awards and honors: National Academy of Sciences Member American Philosophical Society Member Institute of Medicine Member Howard Hughes Medical Institute Investigator Biophysical Society Emily M. Gray Award Harvard Westheimer Medal UCLA Seaborg Medal Technion - Israel Institute of Technology Harvey Prize in Human Health As Director of the UCLA-DOE Institute for Genomics and Proteomics and an HHMI Investigator, Dr. Eisenberg leads significant research initiatives in protein structure and aggregation. His laboratory combines X-ray crystallography, bioinformatics, and biochemical techniques to investigate protein interactions, with particular emphasis on amyloid-forming proteins and their role in disease. The Eisenberg Lab, located in Boyer Hall at UCLA, maintains an active research program investigating the structural basis of protein aggregation. The lab continues to build on its landmark discoveries of amyloid structures while exploring new frontiers in understanding protein misfolding diseases and developing potential therapeutic interventions.
